Newron Pharma's neuropathic pain drug fails in Serena study on NLBP patients pharmabiz.com … in patients with at least moderate Neuropathic Low Back Pain (NLBP) failed to show any significant difference between ralfinamide and placebo.
See original here:
Newron Pharma’s neuropathic pain drug fails in Serena study on NLBP patients – pharmabiz.com
